arXiv subjects

Yuanfang Guan

Publications and source records attributed to Yuanfang Guan.

4 recordsLinked to original sources

arXiv2025

The CausalBench challenge: A machine learning contest for gene network inference from single-cell perturbation data

In drug discovery, mapping interactions between genes within cellular systems is a crucial early step. Such maps are not only foundational for understanding the molecular mechanisms underlying disease biology but also pivotal for formulating hypotheses about potential targets for new medicines. Recognizing the need to elevate the construction of these gene-gene interaction networks, especially from large-scale, real-world datasets of perturbed single cells, the CausalBench Challenge was initiated. This challenge aimed to inspire the machine learning community to enhance state-of-the-art methods, emphasizing better utilization of expansive genetic perturbation data. Using the framework provided by the CausalBench benchmark, participants were tasked with refining the current methodologies or proposing new ones. This report provides an analysis and summary of the methods submitted during the challenge to give a partial image of the state of the art at the time of the challenge. Notably, the winning solutions significantly improved performance compared to previous baselines, establishing a new state of the art for this critical task in biology and medicine.

cs.LG↗

arXiv2020

Deep learning prediction of patient response time course from early data via neural-pharmacokinetic/pharmacodynamic modeling

The longitudinal analysis of patient response time course following doses of therapeutics is currently performed using Pharmacokinetic/Pharmacodynamic (PK/PD) methodologies, which requires significant human experience and expertise in the modeling of dynamical systems. By utilizing recent advancements in deep learning, we show that the governing differential equations can be learnt directly from longitudinal patient data. In particular, we propose a novel neural-PK/PD framework that combines key pharmacological principles with neural ordinary differential equations. We applied it to an analysis of drug concentration and platelet response from a clinical dataset consisting of over 600 patients. We show that the neural-PK/PD model improves upon a state-of-the-art model with respect to metrics for temporal prediction. Furthermore, by incorporating key PK/PD concepts into its architecture, the model can generalize and enable the simulations of patient responses to untested dosing regimens. These results demonstrate the potential of neural-PK/PD for automated predictive analytics of patient response time course.

cs.LG↗

arXiv2020

COVID-19 Evolves in Human Hosts

Today, we are all threatened by an unprecedented pandemic: COVID-19. How different is it from other coronaviruses? Will it be attenuated or become more virulent? Which animals may be its original host? In this study, we collected and analyzed nearly thirty thousand publicly available complete genome sequences for COVID-19 virus from 79 different countries, the previously known flu-causing coronaviruses (HCov-229E, HCov-OC43, HCov-NL63 and HCov-HKU1) and the lethal, pathogenic viruses, SARS, MERS, Victoria, Lassa, Yamagata, Ebola, and Dengue. We found strong similarities between the current circulating COVID-19 and SARS and MERS, as well as COVID-19 in rhinolophines and pangolins. On the contrary, COVID-19 shares little similarity with the flu-causing coronaviruses and the other known viruses. Strikingly, we observed that the divergence of COVID-19 strains isolated from human hosts has steadily increased from December 2019 to May 2020, suggesting COVID-19 is actively evolving in human hosts. In this paper, we first propose a novel MLCS algorithm NP-MLCS1 for the big sequence analysis, which can calculate the common model for COVID-19 complete genome sequences to provide important information for vaccine and antibody development. Geographic and time-course analysis of the evolution trees of the human COVID-19 reveals possible evolutional paths among strains from 79 countries. This finding has important implications to the management of COVID-19 and the development of vaccines and medications.

q-bio.PE↗

arXiv2019

Lung cancer screening with low-dose CT scans using a deep learning approach

Lung cancer is the leading cause of cancer deaths. Early detection through low-dose computed tomography (CT) screening has been shown to significantly reduce mortality but suffers from a high false positive rate that leads to unnecessary diagnostic procedures. Quantitative image analysis coupled to deep learning techniques has the potential to reduce this false positive rate. We conducted a computational analysis of 1449 low-dose CT studies drawn from the National Lung Screening Trial (NLST) cohort. We applied to this cohort our newly developed algorithm, DeepScreener, which is based on a novel deep learning approach. The algorithm, after the training process using about 3000 CT studies, does not require lung nodule annotations to conduct cancer prediction. The algorithm uses consecutive slices and multi-task features to determine whether a nodule is likely to be cancer, and a spatial pyramid to detect nodules at different scales. We find that the algorithm can predict a patient's cancer status from a volumetric lung CT image with high accuracy (78.2%, with area under the Receiver Operating Characteristic curve (AUC) of 0.858). Our preliminary framework ranked 16th of 1972 teams (top 1%) in the Data Science Bowl 2017 (DSB2017) competition, based on the challenge datasets. We report here the application of DeepScreener on an independent NLST test set. This study indicates that the deep learning approach has the potential to significantly reduce the false positive rate in lung cancer screening with low-dose CT scans.

eess.IV↗